Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Christian PfisterGwenaëlle GravisAude FléchonChristine ChevreauHakim MahammediBrigitte LaguerreAline GuillotFlorence Joly LobbedezMichel SouliéYves AlloryValentin HarterStephane Culinenull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In the VESPER trial, dd-MVAC improved 3-years PFS over GC. In the neoadjuvant group, a better bladder tumor local control and a significant improvement in 3-year PFS were observed in the dd-MVAC arm.
Keyphrases
- locally advanced
- muscle invasive bladder cancer
- phase iii
- study protocol
- rectal cancer
- phase ii
- clinical trial
- squamous cell carcinoma
- lymph node
- drug delivery
- cardiac surgery
- patients undergoing
- open label
- randomized controlled trial
- high dose
- cancer therapy
- low dose
- acute kidney injury
- mass spectrometry
- high resolution
- placebo controlled